Which Drug-Eluting Stent Is Best for Left Main Lesions?

In a randomized trial, PES and SES produced similarly good results.

In this randomized equivalence study, investigators compared paclitaxel-eluting stents (PES) with sirolimus-eluting stents (SES) in 607 patients undergoing percutaneous coronary intervention for unprotected left main coronary artery (LMCA) stenoses. Of the study population, 23% were women, nearly 30% had diabetes, 42% presented with acute coronary syndromes, about one third were high-risk surgical candidates, and two thirds had three-vessel disease. Distal LMCA lesions were present in 63% of patients, and about 50% underwent culotte bifurcation stenting. Intravascular ultrasound was not used.

Definite stent thrombosis occurred in one PES recipient (0.3%) and in two SES recipients (0.7%); this difference was not statistically significant (rel…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI